obstructive sleep apnea

View All

Pharma News for Amylyx, Sellas, Apnimed, Ocelot
ImPact Biotech’s IND Application for Padeliporfin VTP; Orphan Drug Designation to Ocelot Bio’s OCE-205 for Ascites; Amylyx’s Phase 3 ORION Study of AMX0035 for PSP; SELLAS Receives FDA Orphan Drug Designation for SLS009 for PTCL Treatment; Apnimed Updated on Second Phase 3 Clinical Study of AD109 for OSA

ImPact Biotech Receives FDA Clearance of IND Application for Padeliporfin VTP in Pancreatic Cancer ImPact Biotech, a biotechnology company in its clinical stage dedicated to advancing Padeliporfin Vascular Targeted Photodynamic (VTP) therapy for various solid tumors, announced on December 20, 2023, that the U.S....

Find More

Sleep Aids Market
Sleep Aids Market: Examining Cutting-Edge Technologies and Major Breakthroughs

Sleep Aids Market: Examining Cutting-Edge Technologies and Scientific Breakthroughs Sleep can be burdensome when it disrupts daily routines, requires a significant time commitment, and is marred by sleep disorders or disturbances that affect overall well-being. In today's fast-paced world, where stress, anxiety,...

Find More

Anti-snoring Devices Market
Exploring the World of Anti-snoring Devices: A Comprehensive Market Assessment

Snoring, a common sleep-related issue, can disrupt both the snorer's sleep and that of their partner or roommate. As per the estimate, about 90 million Americans suffer from snoring, either temporarily or semi-permanently, due to colds, allergies, or other factors. Snoring can have several implications, and it can ...

Find More

ATS 2023 Updates: AD109’s Potential as the First Oral Medication for Obstructive Sleep Apnea (OSA)

Apnimed’s AD109 has the potential to be the first oral pharmaceutical drug that remedies both, the primary cause of OSA, nocturnal airway obstruction, and the daytime symptoms of OSA, such as fatigue. The dual mode of action of AD109 leads to upper airway dilatation as well as enhanced breathing and oxygen...

Find More

MedTech News and Updates for Vivos, Arthrex, Chindex, Glaukos, Zimmer Biomet
Vivos Therapeutics ‘s DNA Oral Appliance for the Treatment of OSA; Arthrex’s TightRope Implant for Pediatric ACL Surgery; Chindex Medical Acquired 10 ViewRay MRIdian Systems; Zimmer Biomet to Acquire Embody; GE HealthCare to buy IMACTIS; Glaukos Announced the iDose TR Exchange Trial

Vivos Therapeutics Received FDA 510(k) Clearance for its Flagship DNA Oral Appliance for the Treatment of Obstructive Sleep Apnea On January 4, 2023, Vivos Therapeutics, Inc., a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mil...

Find More

Obstructive Sleep Apnea
Covering the Therapeutic Advancements in Obstructive Sleep Apnea Treatment Scenario

Obstructive Sleep Apnea (OSA) is a common, chronic, sleep-related breathing disorder characterized by periodic narrowing and obstruction of the pharyngeal airway during sleep, leading to either complete or partial obstruction of the airway, resulting in apneas, hypopneas, or both. Obstructive Sleep Apnea causes day...

Find More

MedTech News and Updates for LivaNova, Medtronic, Conformis, Noninvasix, Masimo
Noninvasix’s LIVOx™ Central Venous Oxygenation Monitor; LivaNova’s aura6000 System; Oxford BioDynamics’s EpiSwitch® CiRT; Masimo’s SedLine® Brain Function Monitoring and the SedLine Pediatric EEG Sensor; Medtronic’s NuVent™ Eustachian Tube Dilation Balloon; Conformis’s published data for Bilateral Knee Implant Study

Noninvasix Granted the US FDA Breakthrough Device Designation for Non-Invasive Monitoring Technology for Sepsis On February 23, 2022, Noninvasix, Inc. received the US FDA breakthrough device designation for its LIVOx™ Central Venous Oxygenation Monitor. It is a non-invasive device and provides real-time, ...

Find More

Narcolepsy
Narcolepsy now a confirmed Autoimmune Disorder

The concept of sleep as a passive movement of unconsciousness has long been ruled out. But this act of rejuvenation hasn't just been restricted to the phase of resting. Usually, sleepers undergo five stages of sleep consisting of both REM (Rapid Eye Movement) and N-REM (Non- Rapid Eye Movement), each lasting f...

Find More